Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 215 (Mvasi) vs Bevacizumab in Advanced NSCLC
NCT01966003Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2013
- Primary completion
- Jul 2015
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Amgen. Started Nov 2013; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01966003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01966003.